Home › Funds › DELTEC ASSET MANAGEMENT LLC › OCUL

DELTEC ASSET MANAGEMENT LLC position in OCUL

OCULAR THERAPEUTIX INC · Health Care

DELTEC ASSET MANAGEMENT LLC reported holding 2,623,597 shares of OCUL (OCULAR THERAPEUTIX INC) in its Q3 2026 13F filing — a position valued at US$20.1M, representing 3.17% of its reported portfolio and ranking #7 among its reported holdings. DELTEC ASSET MANAGEMENT LLC has disclosed OCUL holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)2.62M sh
Reported value held$20.12M
Portfolio Weight3.17%
First reportedQ3 2023
Last changeAdd
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How DELTEC ASSET MANAGEMENT LLC's OCUL position evolved

DELTEC ASSET MANAGEMENT LLC first disclosed a stake in OCUL in Q3 2023 at 2,061,797 shares (US$6.5M). The position peaked in Q3 2025 at 2,762,459 shares, worth US$32.3M. Across 13 filings, DELTEC ASSET MANAGEMENT LLC increased the stake 7 time(s), trimmed it 4 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 2,623,597 shares valued at US$20.1M — an increase of 147,400 shares quarter over quarter..

Quarter by quarter

QuarterSharesValueChange
Q3 2023 2.06M $6.47M New
Q4 2023 2.44M $10.90M Add
Q1 2024 2.36M $21.51M Reduce
Q2 2024 2.59M $17.72M Add
Q3 2024 2.60M $22.62M Hold
Q4 2024 2.62M $22.34M Add
Q1 2025 2.72M $19.91M Add
Q2 2025 2.79M $25.94M Add
Q3 2025 2.76M $32.29M Reduce
Q4 2025 2.49M $30.20M Reduce
Q1 2026 2.34M $19.83M Reduce
Q2 2026 2.48M $24.32M Add
Q3 2026 2.62M $20.12M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About OCUL and 13F data

OCUL (OCULAR THERAPEUTIX INC) is a Health Care company. 37 other funds we track also report a position in OCUL — the largest reported positions include Deep Track Capital, LP (US$193.3M), Avoro Capital Advisors LLC (US$123.1M), Venrock Adviser, LLC (US$101.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding OCUL

All OCUL fund holders →

FAQ

How long has DELTEC ASSET MANAGEMENT LLC held OCUL?

DELTEC ASSET MANAGEMENT LLC has disclosed OCUL holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is DELTEC ASSET MANAGEMENT LLC's current position in OCUL?

As of Q3 2026, DELTEC ASSET MANAGEMENT LLC holds 2.62M shares of OCUL (OCULAR THERAPEUTIX INC), valued at $20.12M, representing 3.17% of its reported portfolio and ranking #7.

Has DELTEC ASSET MANAGEMENT LLC been buying or selling OCUL?

In the latest 13F filing (Q3 2026), DELTEC ASSET MANAGEMENT LLC increased its position in OCUL. The position peaked in Q3 2025 at 2.76M shares.

Which other funds hold OCUL?

Other major institutional holders of OCUL include Deep Track Capital, LP, Avoro Capital Advisors LLC, Venrock Adviser, LLC, among 37 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.